Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center

Articles by Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center

Impact of Recent Clinical Data on Treatment for HER2+ MBC

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Treatment Choice for Patient Relapsing With Brain Metastases

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2CLIMB: Brain Metastases Data

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

HER2+ Early-Stage Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Guidelines and Approaches to HER2 Testing for Breast Cancer

ByAdam Brufsky, MD, PhD, UPMC Hillman Cancer Center,Carey K. Anders, MD, Duke Cancer Institute,Virginia Kaklamani, MD, University of Texas Health Science Center,Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center,Mark D. Pegram, MD, Stanford Cancer Center

June 30th 2020

Dr. Murthy on HER2CLIMB Trial Results in HER2+ Breast Cancer

ByRashmi K. Murthy, MD, MBE, MD Anderson Cancer Center

December 12th 2019

Rashmi K. Murthy, MD, MBE, discusses results of the HER2CLIMB trial in previously treated HER2-positive breast cancer.

Latest Updated Articles

Dr. Murthy on HER2CLIMB Trial Results in HER2+ Breast Cancer
December 12th 2019
TRAIN-2: Anthracyclines in HER2+ Breast Cancer
June 30th 2020
Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer
June 30th 2020
Guidelines and Approaches to HER2 Testing for Breast Cancer
June 30th 2020
HER2CLIMB: Brain Metastases Data
June 30th 2020
Treatment Choice for Patient Relapsing With Brain Metastases
June 30th 2020

Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center

Articles by Rashmi K. Murthy, MD, MBE, MD Anderson Cancer Center

Impact of Recent Clinical Data on Treatment for HER2+ MBC

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

Treatment Choice for Patient Relapsing With Brain Metastases

HER2CLIMB: Brain Metastases Data

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

HER2+ Early-Stage Breast Cancer

Guidelines and Approaches to HER2 Testing for Breast Cancer

Dr. Murthy on HER2CLIMB Trial Results in HER2+ Breast Cancer

Latest Updated Articles

Trending on OncLive

Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC

Five Under 5: Top Oncology Videos for the Week of 6/28

The OncFive: Top Oncology Articles for the Week of 6/28

Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera

FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification